Grant: CIHR Fellowship
University of British Columbia
$45,000.00
Targeting HSP90 in prostate cancer bone microenvironment by using a novel inhibitor: SNX-5422
EF 2009-10
Résumé
The prostate cancer is the most common cancer in men and is the second leading cause of cancer death in men after lung cancer. In more than 80% of cases, the prostate cancer is associated with the development of bone metastases responsible for bone pain and pathologic fractures. Current treatment is based on anti-androgen therapies; however, after 18 to 36 months, progression to castration resistant disease frequently occurs. At this stage there is no cure but only palliative treatments to improve the quality of life of patients with particular relief of bone pain. Consequently there is an urgent need for novel therapeutic agents that can prevent the emergence of the castration resistant form of disease. HSP 90 or heat shock protein 90 is crucial for the maturation and stability of many proteins involved in prostate cancer development and, as such, is a new target to treat prostate cancer and bone metastasis. Currently, 17-AAG, an inhibitor of HSP90 is in the last stage of clinical trial. 17-AAG has a great anti-tumor activity in prostate cancer, but several studies report that this drug is responsible of secondary effect, as it increases tumor progression in bone metastasis by differentiation and activation of osteoclasts, which are the cells responsible for bone destruction. Up to date, there is no treatment to cure both prostate cancer and bone metastasis. The important and urgent challenge faced by researchers is to develop a treatment against both prostate cancer and development of bone metastasis. In this proposal, we will assess the in vivo antitumor properties of a novel synthetic HSP90 inhibitor, SNX-5422, in bone metastasis prostate cancer using preclinical models. The extremely encouraging preliminary results demonstrate that this inhibitor possesses a significant anti-tumor activity in primary prostate cancer and inhibits differentiation and activation of osteoclasts.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
203479
Name
Lamoureux Francois
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Not applicable / Specified
Prcname2
Fellowships - Post-PhD
Projecttitle
Targeting HSP90 in prostate cancer bone microenvironment by using a novel inhibitor: SNX-5422
Programtype2
Fellowship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bone Metastasis; Cell Biology; Heat Shock Protein; Hsp90 Inhibitor; Pre-Clinical Model; Prostate Cancer; Therapeutic Approach; Tumor Bone Microenvironment
Abstract
The prostate cancer is the most common cancer in men and is the second leading cause of cancer death in men after lung cancer. In more than 80% of cases, the prostate cancer is associated with the development of bone metastases responsible for bone pain and pathologic fractures. Current treatment is based on anti-androgen therapies; however, after 18 to 36 months, progression to castration resistant disease frequently occurs. At this stage there is no cure but only palliative treatments to improve the quality of life of patients with particular relief of bone pain. Consequently there is an urgent need for novel therapeutic agents that can prevent the emergence of the castration resistant form of disease. HSP 90 or heat shock protein 90 is crucial for the maturation and stability of many proteins involved in prostate cancer development and, as such, is a new target to treat prostate cancer and bone metastasis. Currently, 17-AAG, an inhibitor of HSP90 is in the last stage of clinical trial. 17-AAG has a great anti-tumor activity in prostate cancer, but several studies report that this drug is responsible of secondary effect, as it increases tumor progression in bone metastasis by differentiation and activation of osteoclasts, which are the cells responsible for bone destruction. Up to date, there is no treatment to cure both prostate cancer and bone metastasis. The important and urgent challenge faced by researchers is to develop a treatment against both prostate cancer and development of bone metastasis. In this proposal, we will assess the in vivo antitumor properties of a novel synthetic HSP90 inhibitor, SNX-5422, in bone metastasis prostate cancer using preclinical models. The extremely encouraging preliminary results demonstrate that this inhibitor possesses a significant anti-tumor activity in primary prostate cancer and inhibits differentiation and activation of osteoclasts.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lamoureux, Francois
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $45,000~ $0~